Anderson, Rebecca
Miller, Lance D. http://orcid.org/0000-0003-3799-2528
Isom, Scott
Chou, Jeff W.
Pladna, Kristin M.
Schramm, Nathaniel J.
Ellis, Leslie R.
Howard, Dianna S.
Bhave, Rupali R.
Manuel, Megan
Dralle, Sarah
Lyerly, Susan
Powell, Bayard L.
Pardee, Timothy S. http://orcid.org/0000-0002-1186-6948
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA197991-01A1)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P30CA012197)
Article History
Received: 30 November 2020
Accepted: 22 February 2022
First Online: 30 March 2022
Competing interests
: T.S.P. and B.L.P. are paid consultants of Rafael Pharmaceuticals and T.S.P. is Co-Chief Medical Officer. T.S.P. receives research funding from Rafael Pharmaceuticals who owns the licensing rights to CPI-613 and is currently developing it for use in oncology patients. Rafael Pharmaceuticals had no input over the design of the protocol as it was initiated as an investigator-sponsored trial by T.S.P. prior to his consultancy and role as Co-Chief Medical Officer. Rafael Pharmaceuticals had no approval rights over the manuscript. The remaining authors declare no competing interests.